COMMD1 Antibody

What is COMMD1 and what are its primary cellular functions?

COMMD1 is a prototypical member of the COMMD gene family that has been shown to inhibit both NF-κB– and HIF-mediated gene expression . This multifunctional protein participates in several critical cellular pathways:

• Regulation of transcription factor activity, including inhibition of both NF-κB and HIF-mediated gene expression

• Promotion of protein ubiquitination through interaction with ubiquitin ligase complexes

• Modulation of copper metabolism and homeostasis

• Binding to nuclear envelope proteins such as lamin A, suggesting potential roles in nuclear architecture and function

COMMD1 achieves these diverse functions through its ability to interact with multiple protein partners in different cellular compartments, serving as a regulatory hub that integrates various cellular processes.

How does COMMD1 function in cancer biology?

COMMD1 has emerged as a significant player in cancer biology with compelling evidence supporting its tumor-suppressive functions:

• COMMD1 expression is frequently suppressed in human malignancies

• Decreased COMMD1 expression correlates with more invasive tumor phenotypes and worse clinical outcomes

• Direct repression of COMMD1 in human cell lines leads to increased tumor invasion in experimental models

• Increased COMMD1 expression in mouse melanoma cells results in decreased lung metastasis

Mechanistically, COMMD1 inhibits HIF-mediated gene expression by binding directly to the amino terminus of HIF-1α, preventing its dimerization with HIF-1β and subsequent DNA binding and transcriptional activation . This inhibitory action affects the expression of genes known to promote cancer cell invasiveness, including direct targets of HIF .

In clinical samples, greater decreases in COMMD1 expression have been observed in lymph node metastatic tumors compared to primary tumors, and more advanced local tumor invasion (T3 or T4) correlates with greater reductions in COMMD1 expression compared to earlier stage tumors (T2) .

What cellular pathways does COMMD1 regulate?

COMMD1 regulates several critical cellular pathways that impact cell function and disease progression:

• NF-κB Signaling Pathway:

  • COMMD1 promotes ubiquitination and degradation of NF-κB subunits through its interaction with a multimeric ubiquitin ligase containing Elongins B and C, Cul2 and SOCS1

  • It accelerates the termination of NF-κB-mediated transcription by facilitating the removal of NF-κB from chromatin

• HIF-Mediated Hypoxia Response:

  • COMMD1 binds directly to HIF-1α, preventing its dimerization with HIF-1β

  • This inhibition blocks DNA binding and transcriptional activation of hypoxia-response genes

• Protein Ubiquitination and Degradation:

  • COMMD1 interacts with ubiquitin ligase complexes and facilitates substrate recruitment

  • It serves to stabilize the interaction between SOCS1 and RelA, promoting ubiquitination of the latter

  • COMMD1 itself is regulated by ubiquitination, with mutations in its leucine repeats preventing this process and leading to protein stabilization

• Nuclear Architecture:

  • COMMD1 physically interacts with lamin A at the nuclear envelope

  • This interaction suggests potential roles in nuclear structure maintenance and gene expression regulation through chromatin organization

The multifaceted regulatory functions of COMMD1 position it as a critical integrator of cellular responses to stress, inflammation, and oncogenic transformation.

What experimental applications are appropriate for COMMD1 antibodies?

COMMD1 antibodies can be utilized in various experimental approaches, each providing unique insights into COMMD1 biology:

• Protein Detection Methods:

  • Western blotting for quantitative analysis of COMMD1 expression in cell and tissue lysates

  • Immunohistochemistry/immunocytochemistry for visualization of COMMD1 localization and expression patterns

  • Flow cytometry for quantitative analysis of COMMD1 in single cells

• Protein Interaction Studies:

  • Co-immunoprecipitation for identification and confirmation of COMMD1 binding partners

  • Proximity ligation assays for in situ detection of COMMD1 interactions with partners like HIF-1α or lamin A

  • Pull-down assays using COMMD1 antibodies to isolate protein complexes

• Functional Studies:

  • Chromatin immunoprecipitation (ChIP) to assess COMMD1's influence on transcription factor binding to target gene promoters

  • In vitro ubiquitination assays to evaluate COMMD1's role in protein ubiquitination processes

  • Immunodepletion to study the functional consequences of removing COMMD1 from protein mixtures

• Clinical Applications:

  • Tissue microarray analysis to assess COMMD1 expression in tumor samples and correlation with clinical outcomes

  • Prognostic marker evaluation in cancer studies, as low COMMD1 expression has been associated with worse clinical outcomes

These diverse applications make COMMD1 antibodies valuable tools for investigating both the basic biology and disease-related functions of this multifunctional protein.

How can I validate the specificity of a COMMD1 antibody?

Thorough validation of COMMD1 antibodies is crucial for obtaining reliable experimental results:

• Genetic Approach:

  • Use COMMD1 knockout or knockdown models as negative controls to confirm signal specificity

  • Compare antibody signal in wild-type versus COMMD1-deficient samples across multiple applications

  • Correlate protein detection with mRNA expression using RT-PCR or RNA-seq

• Protein Engineering Approach:

  • Overexpress tagged versions of COMMD1 (HA-COMMD1 or FLAG-COMMD1) and confirm detection using both COMMD1 antibody and tag-specific antibodies

  • Test antibody against recombinant COMMD1 protein of known concentration

  • Use domain deletion mutants to map the epitope recognized by the antibody

• Analytical Validation:

  • Perform immunoprecipitation with the COMMD1 antibody followed by mass spectrometry to confirm identity

  • Test for cross-reactivity with other COMMD family members through western blotting

  • Conduct peptide competition assays using the immunizing peptide to block specific binding

• Application-Specific Validation:

  • For immunohistochemistry, compare staining patterns with mRNA expression data from the same tissues

  • For co-immunoprecipitation, confirm pull-down efficiency by comparing input and immunoprecipitated fractions

  • For western blotting, verify detection at the expected molecular weight (~21-23 kDa for COMMD1)

Creating a validation profile across multiple techniques provides confidence in antibody specificity and ensures reliable detection of COMMD1 in experimental systems.

What are the optimal conditions for co-immunoprecipitation with COMMD1 antibodies?

Based on published research methodologies, here are the optimal conditions for co-immunoprecipitation with COMMD1 antibodies:

• Sample Preparation:

  • Use RIPA buffer for whole cell extracts as demonstrated in successful COMMD1 interaction studies

  • Include protease inhibitors and, if studying phosphorylation, phosphatase inhibitors

  • For nuclear interactions (with HIF-1α or lamin A), consider nuclear extraction buffers

• Antibody Selection and Usage:

  • Use approximately 2 μg of antibody per 500 μg of protein sample

  • For endogenous COMMD1, use anti-COMMD1 antibody; for tagged constructs, anti-tag antibodies (HA, FLAG)

  • Pre-clear lysates with appropriate control IgG and protein A/G beads to reduce non-specific binding

• Incubation Parameters:

  • Incubate antibodies with protein samples for 2 hours at 4°C

  • For antibody-protein complex capture, mix with 100 μl of protein A/G-agarose suspension for 24 hours at 4°C

  • Maintain gentle agitation during incubation periods to enhance interaction while minimizing disruption

• Washing and Elution:

  • After centrifugation (12,000 × g for 20 sec at 4°C), wash the pellet with appropriate wash buffers

  • Perform multiple washes (3-5) to reduce background while preserving specific interactions

  • Elute bound proteins with SDS sample buffer at 95-100°C for 5 minutes

• Controls and Validation:

  • Include normal mouse IgG (for mouse primary antibodies) or normal rabbit IgG (for rabbit primary antibodies) as negative controls

  • Perform reciprocal IP (pull-down with partner antibody, detect COMMD1) to confirm interactions

  • Include input controls (5-10% of starting material) to assess IP efficiency

These optimized conditions have been successfully used to detect COMMD1 interactions with lamin A and components of ubiquitin ligase complexes , providing a robust framework for investigating novel COMMD1 protein-protein interactions.

How can COMMD1 antibodies be used to study tumor invasion mechanisms?

COMMD1 antibodies can be instrumental in investigating tumor invasion mechanisms through several sophisticated approaches:

• Expression-Invasion Correlation Studies:

  • Use immunohistochemistry with COMMD1 antibodies on tissue microarrays to correlate expression levels with invasion depth, metastasis, and patient survival

  • Quantitatively analyze COMMD1 expression across tumor stages (e.g., T2 vs. T3/T4 in prostate cancer) to establish relationship with invasiveness

  • Combine with markers of epithelial-mesenchymal transition to assess mechanistic relationships

• Molecular Pathway Analysis:

  • Employ chromatin immunoprecipitation (ChIP) to assess how COMMD1 modulates HIF-1 binding to promoters of invasion-related genes (LOX, MMP9, CXCR4)

  • Perform co-immunoprecipitation studies to identify COMMD1 interactions with invasion regulators in different tumor contexts

  • Use proximity ligation assays to visualize and quantify COMMD1-HIF-1α interactions in tumor samples

• Functional Invasion Models:

  • Apply COMMD1 antibodies in chorioallantoic membrane (CAM) assays to track expression during invasion processes

  • Correlate COMMD1 levels with invasion boundaries in 3D spheroid or organoid models

  • Compare COMMD1 expression in primary tumors versus their matched metastases

• Invasion Gene Expression Regulation:

  • Combine COMMD1 immunoprecipitation with analysis of associated chromatin to identify direct regulatory targets

  • Correlate COMMD1 levels with expression of known invasion markers in patient cohorts

  • Perform sequential ChIP (re-ChIP) to determine if COMMD1 and transcription factors co-occupy regulatory regions of invasion genes

Table 1: Correlation between COMMD1 expression and invasion markers in human cancers

These approaches provide comprehensive insights into how COMMD1 regulates tumor invasion through its interactions with transcription factors and modulation of genes involved in cell motility, matrix remodeling, and metastatic potential .

What techniques can be used to investigate COMMD1's interaction with the HIF pathway?

To investigate COMMD1's interaction with the HIF pathway, researchers can employ several advanced techniques:

• Protein-Protein Interaction Analysis:

  • Perform co-immunoprecipitation of COMMD1 with HIF-1α using specific antibodies against both proteins

  • Employ domain mapping through truncated versions of COMMD1 and HIF-1α to identify minimal interaction regions

  • Use structural biology approaches (X-ray crystallography, cryo-EM) to determine the atomic details of the COMMD1-HIF-1α interface

• Functional Dimerization Assays:

  • Conduct electrophoretic mobility shift assays (EMSA) to examine how COMMD1 affects HIF-1α/HIF-1β binding to DNA

  • Perform fluorescence resonance energy transfer (FRET) or bimolecular fluorescence complementation (BiFC) to study COMMD1-HIF-1α interactions in living cells

  • Use native gel electrophoresis to assess HIF-1α/HIF-1β dimerization in the presence/absence of COMMD1

• Transcriptional Regulation Analysis:

  • Implement reporter gene assays using HIF-responsive elements to measure how varying levels of COMMD1 affect HIF transcriptional activity

  • Perform chromatin immunoprecipitation (ChIP) to assess how COMMD1 influences HIF-1 binding to target promoters

  • Use RNA-seq to identify global changes in HIF-regulated gene expression when COMMD1 levels are manipulated

• Hypoxic Response Dynamics:

  • Track COMMD1 and HIF-1α subcellular localization during hypoxia using immunofluorescence microscopy

  • Measure COMMD1-HIF-1α binding kinetics under different oxygen tensions using surface plasmon resonance

  • Analyze post-translational modifications that might regulate the COMMD1-HIF interaction during hypoxia

The mechanistic understanding derived from these studies reveals that COMMD1 inhibits HIF-mediated gene expression by binding directly to the amino terminus of HIF-1α, preventing its dimerization with HIF-1β and subsequent DNA binding and transcriptional activation . This mechanism explains how COMMD1 suppression leads to enhanced expression of HIF target genes involved in tumor invasion and metastasis.

How can researchers study the relationship between COMMD1 and ubiquitination pathways?

Investigating the relationship between COMMD1 and ubiquitination pathways requires specialized techniques:

• Ubiquitination Detection Assays:

  • Immunoprecipitate target proteins (e.g., RelA) in the presence or absence of COMMD1 and blot for ubiquitin

  • Use antibodies specific for different ubiquitin linkages (K48, K63) to determine ubiquitination type

  • Perform in vivo ubiquitination assays using HA-tagged ubiquitin constructs to detect specifically ubiquitinated forms

• Ubiquitin Ligase Complex Analysis:

  • Immunoprecipitate COMMD1 and blot for components of the ECS^SOCS1 ubiquitin ligase complex (Elongins B/C, Cul2, SOCS1)

  • Use tandem affinity purification followed by mass spectrometry to identify all associated ubiquitin ligase components

  • Perform gel filtration chromatography to isolate intact COMMD1-containing ubiquitin ligase complexes

• In Vitro Reconstitution:

  • Reconstitute ubiquitination reactions with purified components (E1, E2, E3 ligase complex containing COMMD1, substrate)

  • Assess how COMMD1 mutations affect ubiquitination activity

  • Compare ubiquitination efficiency with and without COMMD1 to determine its role in the reaction

• Substrate Recruitment Analysis:

  • Investigate how COMMD1 affects the interaction between SOCS1 (the substrate recognition component) and RelA

  • Use competitive binding assays to determine if COMMD1 enhances substrate recruitment to the ligase complex

  • Map the domains in COMMD1 that mediate these interactions through mutational analysis

• COMMD1 Ubiquitination Analysis:

  • Study how modifications to the leucine repeats of COMMD1 prevent its own ubiquitination and stabilize the protein

  • Create COMMD1 mutants with varying stability and assess their impact on target protein ubiquitination

  • Use cycloheximide chase experiments to compare degradation kinetics of wild-type versus mutant COMMD1

Evidence indicates that COMMD1 serves as a critical adaptor in ubiquitin ligase complexes, particularly with the ECS^SOCS1 ligase, where it facilitates substrate binding by stabilizing the interaction between SOCS1 and RelA . This role in protein quality control and degradation provides a mechanistic explanation for COMMD1's influence on multiple cellular pathways.

Why might researchers observe inconsistent COMMD1 staining patterns in different cell types?

Inconsistent COMMD1 staining patterns across different cell types can occur due to several biological and technical factors:

• Expression Level Variations:

  • COMMD1 expression is naturally variable across cell types and tissues

  • In cancer cells, COMMD1 is frequently suppressed, resulting in weaker staining compared to normal cells

  • Different cell types may have different baseline expression levels, requiring optimization of detection parameters

• Subcellular Localization Differences:

  • COMMD1 can localize to different cellular compartments depending on cell type and physiological condition

  • It has been observed at the nuclear envelope (in association with lamin A) as well as in the nucleoplasm

  • The distribution between cytoplasmic and nuclear pools may vary based on cell state and function

• Protein Interaction Effects:

  • Interactions with partners like lamin A , HIF-1α , or components of ubiquitin ligase complexes may mask antibody epitopes

  • Complex formation may sequester COMMD1 in detergent-insoluble compartments, affecting extraction efficiency

  • These interactions may vary by cell type and cellular state, creating apparent differences in staining patterns

• Technical Variables:

  • Different fixation methods may differentially preserve COMMD1 epitopes

  • Nuclear envelope proteins (where COMMD1 can be found with lamin A) may be particularly sensitive to fixation artifacts

  • Antibody concentration, incubation time, and detection systems may need cell type-specific optimization

To address these issues, researchers should:

• Use multiple antibodies targeting different COMMD1 epitopes

• Include positive controls with known COMMD1 expression patterns

• Optimize fixation and permeabilization for each cell type

• Correlate immunostaining with quantitative methods like western blotting

• Consider subcellular fractionation to confirm compartment-specific distribution

How can researchers optimize detection of endogenous versus overexpressed COMMD1?

Optimizing detection of endogenous versus overexpressed COMMD1 requires different approaches:

For Endogenous COMMD1 Detection:

• Antibody Selection:

  • Choose high-affinity antibodies specific to endogenous COMMD1

  • Validate antibody specificity using COMMD1 knockdown or knockout models

  • Consider monoclonal antibodies for higher specificity in complex samples

• Signal Amplification:

  • Use sensitive detection methods like enhanced chemiluminescence (ECL) for western blots

  • Consider signal amplification systems for immunohistochemistry of low-abundance endogenous COMMD1

  • Optimize antigen retrieval methods for tissue sections

• Background Reduction:

  • Increase blocking time and concentration to minimize non-specific binding

  • Use monoclonal antibodies for higher specificity

  • Include appropriate negative controls (isotype controls, COMMD1-depleted samples)

For Overexpressed COMMD1 Detection:

• Expression System Optimization:

  • Note that repeated attempts at generating cell lines stably overexpressing wild-type COMMD1 result in modest or no overexpression

  • Consider using mutant versions (e.g., Mut1/2 with leucine repeat mutations) that show greater protein stability

  • Use inducible expression systems to control expression timing and level

• Tag Selection:

  • Use epitope tags (HA, FLAG) as demonstrated in the literature

  • Position tags carefully to avoid interfering with COMMD1 function or localization

  • Compare detection using both tag-specific and COMMD1-specific antibodies

• Expression Verification:

  • Always verify expression at both protein (western blot) and mRNA levels (qPCR)

  • Include empty vector controls to assess background

  • Quantify relative expression compared to endogenous levels

Table 2: Comparison of detection methods for endogenous vs. overexpressed COMMD1

What controls should be included when studying COMMD1's protein-protein interactions?

When investigating COMMD1's protein-protein interactions, comprehensive controls are essential for reliable results:

• Input Controls:

  • Include whole cell extracts (WCE) to confirm the presence of both COMMD1 and potential interacting partners before immunoprecipitation

  • Quantify relative abundance of proteins in input samples to assess IP efficiency

  • Use 5-10% of starting material as input reference

• Negative Controls for Immunoprecipitation:

  • Include normal mouse IgG (for mouse antibodies) or normal rabbit IgG (for rabbit antibodies) to control for non-specific binding

  • Use isotype-matched control antibodies at the same concentration as the specific antibody

  • Perform immunoprecipitation from cells where COMMD1 or the interaction partner has been knocked down/out

• Reciprocal Co-immunoprecipitation:

  • Perform IP with antibody against COMMD1 and blot for partner protein

  • Perform IP with antibody against partner protein and blot for COMMD1

  • This bidirectional validation strengthens evidence for true interactions

• Interaction Domain Controls:

  • Use deletion or point mutants of COMMD1 to map interaction domains

  • For example, mutations in leucine repeats affect COMMD1 stability and may alter interaction profiles

  • Include corresponding mutations in partner proteins to confirm specificity of interaction domains

• Stimulus-Dependent Interaction Controls:

  • Test interactions under relevant physiological conditions (e.g., hypoxia for HIF interactions, TNF stimulation for NF-κB interactions )

  • Include appropriate time-course analyses to capture dynamic interactions

  • Compare interaction strength before and after relevant stimuli

• Specificity Controls:

  • Test interactions with other COMMD family members to determine specificity

  • Include other proteins from the same family as the interaction partner (e.g., other NF-κB subunits, other lamin proteins)

  • Use competitive binding assays with purified proteins to confirm direct interactions

These comprehensive controls help distinguish genuine protein-protein interactions from technical artifacts and provide insights into the specificity, regulation, and functional significance of COMMD1's diverse protein interactions.

How can COMMD1 antibodies be used to explore its role in aging through lamin A interactions?

COMMD1 antibodies can be powerful tools for investigating its role in aging through lamin A interactions using these advanced approaches:

• Age-Dependent Interaction Analysis:

  • Perform co-immunoprecipitation of COMMD1 and lamin A across different age groups in human or animal tissues

  • Quantify interaction strength using quantitative immunoblotting

  • Combine with proteomic analysis to identify age-dependent changes in the COMMD1-lamin A interactome

• Nuclear Architecture Studies:

  • Use super-resolution microscopy with COMMD1 and lamin A antibodies to assess co-localization at the nuclear envelope

  • Examine how this co-localization changes with cellular aging or in progeria models

  • Investigate nuclear envelope integrity in relation to COMMD1-lamin A interactions

• Transcriptional Regulation in Aging:

  • Perform ChIP-seq using COMMD1 antibodies to identify genomic binding sites in young versus aged cells

  • Compare to lamin-associated domains (LADs) to understand potential cooperative functions

  • Correlate changes in gene expression with alterations in COMMD1-lamin A interactions during aging

• Prelamin A Processing Analysis:

  • Investigate whether COMMD1 interacts differentially with prelamin A versus mature lamin A

  • Examine how COMMD1-lamin interactions are affected in cells with defective lamin A processing

  • Study potential roles of COMMD1 in lamin A maturation or stability

The physical interaction between COMMD1 and lamin A demonstrated through co-immunoprecipitation and co-localization experiments suggests an important functional relationship . Investigating how this interaction changes with age or in age-related pathologies could reveal novel mechanisms connecting COMMD1 to nuclear integrity and aging processes.

What methodological approaches can be used to study post-translational modifications of COMMD1?

Investigating post-translational modifications (PTMs) of COMMD1 requires specialized techniques:

• Identification of PTM Sites:

  • Immunoprecipitate endogenous COMMD1 using specific antibodies and analyze by mass spectrometry

  • Use phospho-specific, ubiquitin-specific, or other PTM-specific antibodies in western blotting

  • Generate site-specific antibodies against predicted PTM sites on COMMD1

• Ubiquitination Analysis:

  • Given COMMD1's known ubiquitination , perform denaturing IP to capture ubiquitinated COMMD1

  • Use antibodies specific for different ubiquitin linkages (K48, K63) to determine ubiquitination type

  • Create mutants of critical leucine repeats that prevent ubiquitination to study functional consequences

• PTM Dynamics:

  • Study how PTMs change following stimuli relevant to COMMD1 function (e.g., hypoxia, TNF stimulation, copper exposure)

  • Use pulse-chase experiments to determine PTM turnover rates

  • Apply SILAC (Stable Isotope Labeling with Amino acids in Cell culture) combined with mass spectrometry for quantitative PTM analysis

• Functional Consequences:

  • Generate PTM-mimetic mutants (e.g., phosphomimetic mutations)

  • Create PTM-deficient mutants (e.g., lysine to arginine mutations for ubiquitination sites)

  • Compare these mutants for effects on protein interactions, localization, and function

Table 3: Known and predicted post-translational modifications of COMMD1

Research has demonstrated that mutations in the leucine repeats of COMMD1 prevented basal ubiquitination with consequent stabilization of the protein . Further investigation of PTMs will enhance our understanding of how COMMD1 function is regulated in different cellular contexts.

How can researchers distinguish between COMMD1's nuclear and cytoplasmic functions?

Distinguishing COMMD1's nuclear functions from its cytoplasmic roles requires specialized experimental approaches:

• Subcellular Fractionation:

  • Perform careful fractionation to separate nuclear, cytoplasmic, and membrane compartments

  • Analyze COMMD1 distribution across fractions using specific antibodies

  • Use COMMD1 antibodies combined with compartment-specific markers in western blotting

• Compartment-Specific Interactome Analysis:

  • Immunoprecipitate COMMD1 from nuclear versus cytoplasmic fractions

  • Identify compartment-specific interaction partners by mass spectrometry

  • Compare interactors like HIF-1α and lamin A (primarily nuclear) versus copper transport proteins (primarily cytoplasmic)

• Targeted Localization Mutants:

  • Create COMMD1 constructs with added nuclear localization signals (NLS) or nuclear export signals (NES)

  • Generate compartment-tethered versions (e.g., by fusion to nuclear membrane or cytoplasmic anchor proteins)

  • Assess functional consequences of restricting COMMD1 to specific compartments

• Function-Specific Assays:

  • For nuclear functions: Reporter gene assays for NF-κB or HIF activity

  • For nuclear envelope functions: Lamin A interaction studies

  • For cytoplasmic functions: Copper transport or trafficking assays

  • Compare effects of wild-type versus compartment-restricted COMMD1

• Dynamic Trafficking Analysis:

  • Monitor COMMD1 translocation after specific stimuli using immunofluorescence

  • For nuclear functions, examine localization after TNF stimulation (NF-κB pathway ) or hypoxia (HIF pathway )

  • Track movement between compartments using live-cell imaging of fluorescently tagged COMMD1

Research has demonstrated that COMMD1 exhibits both nuclear functions (such as interaction with lamin A at the nuclear envelope and regulation of transcription factors like HIF-1α and NF-κB ) and cytoplasmic roles (like copper metabolism). These compartment-specific approaches help delineate how COMMD1 coordinates its diverse cellular functions.